Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Clinical effect of point mutations in myelodysplastic syndromes

    ... including specific cytopenias, the proportion of blasts , and overall survival. RESULTS: We identified somatic ... all comparisons) and an increased proportion of bone marrow blasts (P<0.006 for all comparisons). In a multivariable Cox regression model, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.

    ... to pre-defined criteria ( cellularity <20% and blasts <10%). Marrow cellularity (P<0.0001) and blast% (P=0.03) were ... with inferior OS after HCT (HR=1.22 for each 10% marrow blasts, 95% CI: 1.02-1.46). For AML/MDS patients, there was a suggestion that ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... remissions, and reduction in bone marrow blasts . 5-azacitidine has also been shown to improve overall survival. ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival

    ... 125 cytopenic patients: 40 lower grade MDS (<5% marrow blasts ), 24 higher grade MDS, and 61 benign. RESULTS: CD271+ MSC ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Clinical and genetic predictors of prognosis in myelodysplastic syndromes

    ... blood cytopenias, the proportion of bone marrow blasts , and specific karyotype abnormalities. Other factors including age, ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Myelodysplastic syndromes

    ... marrow with dysplasia, with or without excess of blasts . Prognosis depends largely on the marrow blast percentage, number ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... acute myeloid leukemia with 20-30% bone marrow blasts . Patients were treated with azacitidine, with one of three dosage ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

    ... such as additional chromosomal abnormalities, >5 % blasts in the bone marrow (BM), or transfusion dependence. Over ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... included Intermediate-1 (n=5 patients with excess blasts ), Intermediate-2 (20), and High (11). Common grade 3/4 ...

    Research Article last updated 07/20/2018 - 5:14pm.